<DOC>
	<DOCNO>NCT01069419</DOCNO>
	<brief_summary>This observational , non-interventional , non-comparative , post-authorization safety study evaluate efficacy long-term safety Cimzia adult patient RA need treatment biological product .</brief_summary>
	<brief_title>Observation Treatment With Certolizumab Pegol Daily Practice</brief_title>
	<detailed_description>The purpose study assess clinical efficacy Cimzia achieve clinical remission two year therapy . The observational nature study leave therapeutic decision exclusively within discretion treat physician .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Patients eligible treatment Cimzia define EU approve SmPC Patient previously treat Cimzia . Patient known hypersensitivity component Cimzia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Certolizumab Pegol</keyword>
	<keyword>Cimzia</keyword>
</DOC>